RxDoctor Payments Data

Steven Finley, DO

Family Medicine · Cushing, OKNPI 1356594998

Payments from drug & device makers

$1,409in general payments, 2019–2025

Across 77 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$248
  • AbbVie$203
  • Lilly USA, LLC$189
  • Novo Nordisk$104
  • GSK$85
  • Johnson & Johnson$83
  • plus $497 from 13 others

What the payments were for

  • Food & beverage$1,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,409 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$36,621
Medicare patients
159
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$148,083
OzempicSemaglutide83$90,259
JardianceEmpagliflozin45$43,678
MounjaroTirzepatide33$38,833
ProliaDenosumab18$30,398
XareltoRivaroxaban24$28,951
EntrestoSacubitril/Valsartan29$23,315
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$18,731
JanuviaSitagliptin Phosphate14$18,497
SymbicortBudesonide/Formoterol Fumarate62$17,761
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,279
LinzessLinaclotide16$13,715
Tresiba Flextouch U-100Insulin Degludec25$11,523
FarxigaDapagliflozin Propanediol11$10,653
GemtesaVibegron38$10,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$148,083189 claims
Novo NordiskOzempic$104$90,25983 claims
AstraZenecaBreztri Aerosphere, Symbicort, Farxiga$248$47,14495 claims
Boehringer IngelheimJardiance$69$43,67845 claims
Lilly USA, LLCMounjaro$189$38,83333 claims
AmgenProlia$30$30,39818 claims
Johnson & JohnsonXarelto$83$28,95124 claims
GSKTrelegy Ellipta$85$16,27926 claims
AbbVieLinzess$203$13,71516 claims
Astellas Pharma US IncMyrbetriq$24$7,04720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Cushing

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →